- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03493009
Optimizing the Preparation Regime Prior to Colonoscopy Procedure With Pure-Vu System
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This multicenter, prospective, randomized study will include up to 100 patients (30 patients per site and 15 patients per study arm), aimed at evaluating the performance of Pure-Vu System in cleansing patients' colon who are indicated for colonoscopy procedure using one of two different preparation regimes as detailed below.
Subjects will be enrolled at up to 10 clinical sites in the United States. Subjects who meet the eligibility criteria will be randomly allocated to a given study arm and will be required to follow a specific bowel preparation instruction along with a specific prep agent (Bowel preparation instructions for morning and afternoon procedures are provided in appendix B1 and B2, respectively), as per study arm allocation, starting 5 days prior to the colonoscopy with Pure-Vu. Patients will be asked to record and provide their diet and bowel movements in the provided diary log at time of their scheduled colonoscopy (Diary log is provided in appendix D).
In addition patient will be ask to complete a satisfaction questionnaire include feedback on the procedure and on specific aspects related to the preparation regime.
Following the procedure a telephone follow-up will be conducted at 48 hours (± 48 hours) post Pure-Vu procedure to assess patient well-being and capture any adverse events.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects scheduled for colonoscopy procedure
- Subjects in the age range of 22-75 years inclusive
- Subject is willing and able to participate in the study procedures and to understand and sign the informed consent.
Exclusion Criteria:
- Patients with active Inflammatory Bowel Disease
- Patients with known diverticulitis disease or with prior incomplete colonoscopy due to diverticular disease
- Patients with known bowel obstruction
- Patient with chronic constipation
- History of prior surgery to colon and/or rectum
- ASA (Physical status classification system) ≥ III
- Renal insufficiency (Creatinine ≥ 1.5mg /dL) (based on medical history)
- Abnormal Liver enzymes (ALT/AST ≥ 2 times upper limits of normal) (based on medical history)
- Patients taking anticoagulants drugs (excluding aspirin) or dual antiplatelet therapy
- Patients with known coagulation disorder (INR >1.5).
- Pregnancy (as stated by patient) or breast feeding
- Patients with altered mental status/inability to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 10mg Magnesium citrate
subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 10 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
|
The Pure-Vu System is Food and Drug Administration (FDA) approved device since September 22, 2016, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g.
blood.
|
Experimental: 15mg Magnesium citrate
subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 15 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
|
The Pure-Vu System is Food and Drug Administration (FDA) approved device since September 22, 2016, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g.
blood.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
rate of adequate cleansing level
Time Frame: up to 2 hours
|
The rate of adequate cleansing level in each colon segment before and after use of Pure-Vu will be evaluated per study arm using the Boston Bowel Preparation Scale (BBPS). Segment score of 0-3 given to each of the 3 segments of the colon (Left side, Transverse and right side). BBPS* scores will be rated by the colonoscopies, on the basis of three segment scores summed for maximum score of 9, where:
|
up to 2 hours
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL00042
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Diseases
-
Umeå UniversityRecruitingFunctional Gastrointestinal DisorderSweden
-
The University of Texas Medical Branch, GalvestonCompletedGastrointestinal Disorders, Functional
-
Campus Bio-Medico UniversityRecruitingGastrointestinal Cancer | Gastrointestinal Hemorrhage | Gastrointestinal Lesions | Gastrointestinal Injury | Gastrointestinal Perforation | Gastrointestinal UlcerItaly
-
Chang Gung Memorial HospitalNew Bellus EnterprisesUnknownNeoplasm | Functional Gastrointestinal DisorderTaiwan
-
Dr Anne PayneUniversity of LondonUnknownFunctional Gastrointestinal Disorders in ChildrenUnited Kingdom
-
Massachusetts General HospitalEnrolling by invitationGastrointestinal Dysfunction | Gastrointestinal DiseaseUnited States
-
Jiangxi University of Traditional Chinese MedicineThe First Affiliated Hospital of Nanchang University; Second Affiliated Hospital... and other collaboratorsCompletedGastrointestinal DiseaseChina
-
Virginia Commonwealth UniversityRecruitingFunctional Gastrointestinal DisordersUnited States
-
Assiut UniversityNot yet recruitingFunctional Gastrointestinal Disorders
-
Massachusetts General HospitalMassachusetts Institute of TechnologyEnrolling by invitationFunctional Gastrointestinal DisordersUnited States
Clinical Trials on Pure-Vu System
-
Motus GI Medical Technologies LtdRecruiting
-
Radboud University Medical CenterMotus GI Medical Technologies Ltd; University Medical Center MainzCompletedColorectal Cancer | Bowel Preparation | Colonic AdenomaGermany, Netherlands
-
Motus GI Medical Technologies LtdCompletedColorectal Cancer | Gastrointestinal DiseaseUnited States
-
Motus GI Medical Technologies LtdTerminated
-
Motus GI Medical Technologies LtdWithdrawnColorectal Cancer | Gastrointestinal DiseaseUnited States
-
The Cleveland ClinicMotus GI Medical Technologies LtdTerminatedLower Gastrointestinal Bleeding | Hemostatic DisorderUnited States
-
Children's Hospital Medical Center, CincinnatiRecruitingCardiac Anomaly | Pectus ExcavatumUnited States
-
Hospital General Universitario Gregorio MarañonCompletedBronchial Hyperreactivity | Inhalant UseSpain
-
Andrews Research & Education FoundationEmCyte Corporation; BioSciences Research Associates, IncCompletedKnee OsteoarthritisUnited States
-
National Taiwan University HospitalNational Science and Technology Council, TaiwanNot yet recruitingChronic StrokeTaiwan